.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Novartis
Moodys
QuintilesIMS
Harvard Business School
UBS
Mallinckrodt
Teva
US Department of Justice
Chinese Patent Office

Generated: September 20, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Method of increasing bone toughness and stiffness and reducing fractures
Abstract:The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such as the hip or spine of a person at risk of or suffering from osteoporosis. The method of the invention can reduce the incidence of vertebral fracure, reduce the incidence of multiple vertebral fractures, reduce the severity of vertebral fracture, and/or reduce the incidence of non-vertebral fracture.
Inventor(s): Hock; Janet M. (Indianapolis, IN), Gaich; Gregory A. (Indianapolis, IN), Dere; Willard H. (Westlake Village Ventura, CA)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:09/647,278
Patent Claims: 1. A method for the treatment of osteoporosis in a human subject, comprising administering to said subject human parathyroid hormone (1-34), without concurrent administration of an antiresorptive agent other than vitamin D or calcium, in a daily dose of 20 ug, said treatment for reducing the risk of vertebral and non-vertebral bone fracture, wherein said vitamin D is not a hydroxylated vitamin D or hydroxylated vitamin D metabolite.

2. The method according to claim 1 wherein said human subject is a man or post-menopausal woman.

3. The method according to claim 1 wherein said osteoporosis is steroid-induced.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
QuintilesIMS
US Department of Justice
Farmers Insurance
UBS
Julphar
Daiichi Sankyo
Novartis
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot